Endurance Wealth Management’s VBI Vaccines, Inc. New Common Stock (Canada) VBIV Stock Holding History

Endurance Wealth Management’s Portfolio VBIV Stock Details VBIV Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q2	$0	Sell	391 -1	-0.3%	-$3	﹤0.01%	670
2023 Q1	$3K	Hold	392	–	–	﹤0.01%	592
2022 Q4	$7K	Hold	392	–	–	﹤0.01%	509
2022 Q3	$8K	Hold	392	–	–	﹤0.01%	494
2022 Q2	$9K	Hold	392	–	–	﹤0.01%	493
2022 Q1	$19K	Hold	392	–	–	﹤0.01%	453
2021 Q4	$28K	Hold	392	–	–	﹤0.01%	414
2021 Q3	$38K	Hold	392	–	–	﹤0.01%	381
2021 Q2	$35K	Hold	392	–	–	﹤0.01%	394
2021 Q1	$36K	Hold	392	–	–	﹤0.01%	390
2020 Q4	$27K	Buy	392 +92	+31%	+$7.84K	﹤0.01%	385
2020 Q3	$25K	Buy	+300	New	+$35K	﹤0.01%	370
2020 Q2	–	Sell	-250	Closed	-$13.8K	–	337
2020 Q1	$0	Buy	+250	New	+$9.72K	﹤0.01%	599
2019 Q4	–	Hold	0	–	–	–	426

Other funds holding VBIV

Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Cambridge Investment Research Advisors Fairfield, Iowa $44.6B AUM 28.94% 1-Year Est. Return

Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

GAI

General American Investors New York $1.69B AUM 40.94% 1-Year Est. Return

YIH

Y-Intercept (HK) Hong Kong $5.05B AUM 17.89% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Endurance Wealth Management's VBIV Position: Q2 2023 in Review

Endurance Wealth Management reduced its VBI Vaccines, Inc. New Common Stock (Canada) (VBIV) stake by 0.26% in Q2 2023, selling an estimated $3 and leaving 391 shares worth $0. The position accounts for ﹤0.01% of the portfolio, ranked #670.

Endurance Wealth Management first reported a position in VBIV in Q1 2020 and has held it in 13 quarters since. The position peaked at $38K in Q3 2021. 46 funds tracked by Wall St. Rank hold VBIV as of Q2 2023.

Endurance Wealth Management held 391 shares of VBI Vaccines, Inc. New Common Stock (Canada) worth $0 as of Q2 2023.
Endurance Wealth Management sold 1 VBI Vaccines, Inc. New Common Stock (Canada) share in Q2 2023, an estimated $3.
VBI Vaccines, Inc. New Common Stock (Canada) made up ﹤0.01% of Endurance Wealth Management's portfolio in Q2 2023, its #670 holding.
Endurance Wealth Management first reported a position in VBI Vaccines, Inc. New Common Stock (Canada) in Q1 2020 and has held it in 13 quarters since.
Endurance Wealth Management's VBI Vaccines, Inc. New Common Stock (Canada) position peaked at $38K in Q3 2021.
46 funds tracked by Wall St. Rank held VBI Vaccines, Inc. New Common Stock (Canada) as of Q2 2023.

Based on Endurance Wealth Management's 13F filing for Q2 2023, filed 9 Aug 2023.